June 25th 2022
Generics of Viibryd, Tranxane and Timoptic have recently been approved and launched.
June 24th 2022
Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.
June 24th 2022
Benefits leaders surveyed in PSG’s Trends in Drug Benefit Design Report say the importance of the member experience has increased since the start of the pandemic.
June 23rd 2022
Elacestrant is oral therapy that targets estrogen receptor 1, a key resistance mechanism in advanced breast cancer.
June 23rd 2022
The FDA approved the combination of Tafinlar and Mekinist for solid tumors with a BRAF V600E mutation. This is the first therapy to be approved that is tumor agnostic for patients with this mutation.